<DOC>
	<DOCNO>NCT01196871</DOCNO>
	<brief_summary>The purpose study determine effect AT1001 safety agalsidase , effect agalsidase safety AT1001 .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Between AT1001 Agalsidase Subjects With Fabry Disease</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Male diagnose Fabry disease 18 65 year age , inclusive Body mass index 1835 Subject initiate treatment agalsidase lease one month , receive least two infusion , Screening Visit Subject 's dose level , dose regimen form agalsidase stable least one month Screening Visit Subject estimate creatinine clearance great equal 50mL/min Screening Subject agree use medicallyaccepted method contraception study 30 day study completion Subject willing able provide write informed consent Subject document transient ischemic attack , ischemic stroke , unstable angina , myocardial infarction within 3 month Screening Subject clinically significant unstable cardiac disease ( e.g. , cardiac disease require active management , symptomatic arrhythmia , unstable angina , NYHA class III IV congestive heart failure ) Subject history allergy sensitivity study drug ( include excipients ) iminosugars ( e.g. , miglustat , miglitol ) Subject require concomitant medication prohibit protocol : Glyset® ( miglitol ) , Zavesca® ( miglustat ) Any investigational/experimental drug device within 30 day Screening , except use investigational ERT Fabry Disease Subject intercurrent illness condition may preclude subject fulfil protocol requirement suggest investigator potential subject may unacceptable risk participate study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>drug drug interaction</keyword>
</DOC>